254 related articles for article (PubMed ID: 30679950)
1. Targeted literature review of the global burden of gastric cancer.
Casamayor M; Morlock R; Maeda H; Ajani J
Ecancermedicalscience; 2018; 12():883. PubMed ID: 30679950
[TBL] [Abstract][Full Text] [Related]
2. Global retrospective analysis of clinician- and patient-reported clinical characteristics and humanistic burden of patients with gastroesophageal cancers on first-line treatment.
Xiao H; Bertwistle D; Khela K; Middleton-Dalby C; Hall J
BMC Cancer; 2023 Feb; 23(1):186. PubMed ID: 36823552
[TBL] [Abstract][Full Text] [Related]
3. Trifluridine/tipiracil in patients with metastatic gastroesophageal junction cancer: a subgroup analysis from the phase 3 TAGS study.
Mansoor W; Arkenau HT; Alsina M; Shitara K; Thuss-Patience P; Cuffe S; Dvorkin M; Park D; Ando T; Van Den Eynde M; Beretta GD; Zaniboni A; Doi T; Tabernero J; Ilson DH; Makris L; Benhadji KA; Van Cutsem E
Gastric Cancer; 2021 Jul; 24(4):970-977. PubMed ID: 33713215
[TBL] [Abstract][Full Text] [Related]
4. A Comparison of Real-World Treatment Patterns and Clinical Outcomes in Patients Receiving First-Line Therapy for Unresectable Advanced Gastric or Gastroesophageal Junction Cancer Versus Esophageal Adenocarcinomas.
Shankaran V; Xiao H; Bertwistle D; Zhang Y; You M; Abraham P; Chau I
Adv Ther; 2021 Jan; 38(1):707-720. PubMed ID: 33244736
[TBL] [Abstract][Full Text] [Related]
5. Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives.
Taieb J; Moehler M; Boku N; Ajani JA; Yañez Ruiz E; Ryu MH; Guenther S; Chand V; Bang YJ
Cancer Treat Rev; 2018 May; 66():104-113. PubMed ID: 29730461
[TBL] [Abstract][Full Text] [Related]
6. Novel Frontiers of Treatment for Advanced Gastric or Gastroesophageal Junction Cancer (GC/GEJC): Will Immunotherapy Be a Future Direction?
Bai R; Chen N; Liang T; Li L; Lv Z; Lv X; Cui J
Front Oncol; 2020; 10():912. PubMed ID: 32793461
[TBL] [Abstract][Full Text] [Related]
7. Real-world Treatment Patterns and Clinical Outcomes Across Lines of Therapy in Patients With Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer.
Le DT; Ott PA; Korytowsky B; Le H; Le TK; Zhang Y; Maglinte GA; Abraham P; Patel D; Shangguan T; Chau I
Clin Colorectal Cancer; 2020 Mar; 19(1):32-38.e3. PubMed ID: 31813769
[TBL] [Abstract][Full Text] [Related]
8. IDF Diabetes Atlas estimates of 2014 global health expenditures on diabetes.
da Rocha Fernandes J; Ogurtsova K; Linnenkamp U; Guariguata L; Seuring T; Zhang P; Cavan D; Makaroff LE
Diabetes Res Clin Pract; 2016 Jul; 117():48-54. PubMed ID: 27329022
[TBL] [Abstract][Full Text] [Related]
9. The Use of Epidermal Growth Factor Receptor Type 2-Targeting Tyrosine Kinase Inhibitors in the Management of Epidermal Growth Factor Receptor Type 2-Positive Gastric Cancer: A Narrative Review.
AlMazmomy AM; Al-Hayani MM; Alomari M; Bazi AG
Cureus; 2019 Dec; 11(12):e6295. PubMed ID: 31938588
[TBL] [Abstract][Full Text] [Related]
10. Immune checkpoint inhibitors for treatment of advanced gastric or gastroesophageal junction cancer: Current evidence and future perspectives.
Zhang Z; Xie T; Zhang X; Qi C; Shen L; Peng Z
Chin J Cancer Res; 2020 Jun; 32(3):287-302. PubMed ID: 32694895
[TBL] [Abstract][Full Text] [Related]
11. The Impact of Inflammatory Bowel Disease in Canada 2018: Indirect Costs of IBD Care.
Kuenzig ME; Lee L; El-Matary W; Weizman AV; Benchimol EI; Kaplan GG; Nguyen GC; Bernstein CN; Bitton A; Lee K; Cooke-Lauder J; Murthy SK
J Can Assoc Gastroenterol; 2019 Feb; 2(Suppl 1):S34-S41. PubMed ID: 31294383
[TBL] [Abstract][Full Text] [Related]
12. The burden of skeletal-related events in four Latin American countries: Argentina, Brazil, Colombia, and Mexico.
Garcia Perlaza J; Aziziyeh R; Zhou A; De Sousa Barbosa V; Amaya J; Caporale J; Alva ME; Forero J; Tanaka S; Suri G; Garcia D
J Med Econ; 2021; 24(1):983-992. PubMed ID: 34325606
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the efficacy and safety of third-line treatments for advanced gastric cancer: A systematic review and network meta-analysis.
Zhang C; Xiang Y; Wang J; Yan D
Front Oncol; 2023; 13():1118820. PubMed ID: 36937403
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness and safety of anti-PD-1 monotherapy or combination therapy in Chinese advanced gastric cancer: A real-world study.
Li T; Liu T; Zhao L; Liu L; Zheng X; Wang J; Zhang F; Hu Y
Front Oncol; 2022; 12():976078. PubMed ID: 36686795
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of targeted drugs in advanced or metastatic gastric and gastroesophageal junction cancer: A network meta-analysis.
Gong H; Su Y; Zhao L; Ma L; Zhang L; Hou L; Li T; Niu S; Zhang H; Li C; Jin X; Ge L; Leng G; Liu Y
J Clin Pharm Ther; 2022 Apr; 47(4):493-506. PubMed ID: 34796971
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of PD-1/PD-L1 inhibitors in gastric or gastro-oesophageal junction cancer based on clinical characteristics: a meta-analysis.
Huo G; Liu W; Chen P
BMC Cancer; 2023 Feb; 23(1):143. PubMed ID: 36765356
[TBL] [Abstract][Full Text] [Related]
17. The humanistic and economic burden of atopic dermatitis among adults and adolescents in Saudi Arabia.
Elezbawy B; Fasseeh AN; Fouly E; Esba LCA; Al Abdulkarim H; Al-Haddab M; Al-Sheikh A; Altawil E; Al Turaiki A; Eshmawi M; Hamadah I; Tannira M; Dalle H; Aderian S; Roshdy A; Jaheen A; Hamad T; Abaza S; Kaló Z
J Med Econ; 2022; 25(1):1231-1239. PubMed ID: 36426726
[TBL] [Abstract][Full Text] [Related]
18. First-line nivolumab plus chemotherapy
Cao X; Zhang M; Li N; Zheng B; Liu M; Song X; Cai H
Ther Adv Med Oncol; 2023; 15():17588359231171038. PubMed ID: 37223263
[TBL] [Abstract][Full Text] [Related]
19. Population-level economic burden of lung cancer in China: Provisional prevalence-based estimations, 2017
Liu C; Shi J; Wang H; Yan X; Wang L; Ren J; Parascandola M; Chen W; Dai M
Chin J Cancer Res; 2021 Feb; 33(1):79-92. PubMed ID: 33707931
[TBL] [Abstract][Full Text] [Related]
20. The burden of osteoporosis in four Latin American countries: Brazil, Mexico, Colombia, and Argentina.
Aziziyeh R; Amin M; Habib M; Garcia Perlaza J; Szafranski K; McTavish RK; Disher T; Lüdke A; Cameron C
J Med Econ; 2019 Jul; 22(7):638-644. PubMed ID: 30835577
[No Abstract] [Full Text] [Related]
[Next] [New Search]
